Newsfeeds Archive - Spark Newswire

1 minute read

CSL and Arcturus Therapeutics Announce Nature Communications Has Published Pivotal Data Demonstrating Efficacy And Tolerability Of COVID-19 Vaccine

May 20, 8:42 AM

Data follow the approval of the world's first self-amplifying (sa-mRNA) COVID-19 vaccine for adults in Japan. These results add to recently published data on ARCT-154 demonstrating superior immunogenicity to Omicron

ARCT

2 minute read

ARS Pharmaceuticals Submits Response For neffy Marketing Authorization Application To EMA’s CHMP And Enters License Agreement With CSL Seqirus For Commercialization Of neffy In Australia And New Zealand

By Benzinga Newsdesk

April 30, 9:23 AM

CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat dose PK/PD study of

CSLLY

2 minute read

FDA Green Lights Pfizer’s Gene Therapy For Rare Bleeding Disorder Hemophilia

By Vandana Singh

April 26, 2:30 PM

FDA approves Pfizer's Beqvez for adults with hemophilia B, offering a one-time treatment to produce FIX. Experience reduced bleeding frequency. Explore Pfizer's warranty program.

CSLLY

2 minute read

Arcturus Therapeutics’ Lung Disease Candidate Triggers Bullish Rating, Analyst Sees Over 200% Upside

By Vandana Singh

December 13, 2:34 PM

Canaccord Genuity has initiated coverage on Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT), a player in the genetic medicine space.

ARCT

2 minute read

Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment

By Vandana Singh

February 21, 8:41 AM

The FDA granted accelerated approval to Travere Therapeutics Inc’s (NASDAQ:TVTX) Filspari (sparsentan) to reduce proteinuria in adults with primary IgAN at risk…

CSLLY

1 minute read

CSL Posts Encouraging Data From Garadacimab In Severe Swelling Attacks

By Vandana Singh

August 17, 12:10 PM

CSL (OTC:CSLLY) announced topline Phase 3 results for garadacimab (CSL312) for hereditary angioedema (HAE). HAE is a rare genetic condition that…

CSLLY

Latest news

CSL and Arcturus Therapeutics Announce Nature Communications Has Published Pivotal Data Demonstrating Efficacy And Tolerability Of COVID-19 Vaccine

ARS Pharmaceuticals Submits Response For neffy Marketing Authorization Application To EMA’s CHMP And Enters License Agreement With CSL Seqirus For Commercialization Of neffy In Australia And New Zealand

FDA Green Lights Pfizer’s Gene Therapy For Rare Bleeding Disorder Hemophilia

Arcturus Therapeutics’ Lung Disease Candidate Triggers Bullish Rating, Analyst Sees Over 200% Upside

Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment

CSL Posts Encouraging Data From Garadacimab In Severe Swelling Attacks